Monomorphic Post-transplant Lymphoproliferative Disorder After Kidney Transplantation and Hematopoietic Stem Cell Transplantation: Clinicopathological Characteristics, Treatments and Prognostic Factors

Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion
Li FuZhao Wang

Abstract

Post-transplant lymphoproliferative disorders (PTLDs) are a heterogeneous group of lymphoid neoplasms associated with immunosuppression following transplantation. Among PTLDs, monomorphic PTLD (m-PTLD) is the largest category; however, its characteristics and survival outcome are not fully understood because of low incidence. This study enrolled 30 adult patients with m-PTLD after kidney-transplantation (KT, n = 17) and hematopoietic stem cell transplantation (HSCT, n = 13) from January 1998 to December 2014. The incidence rates of m-PTLD were 0.74 and 3.63% in the KT and HSCT groups, respectively. M-PTLD patients in the HSCT group were younger and showed earlier onset, with EBV-encoded small RNAs (EBER) more frequently identified. Diffuse large B cell lymphoma (DLBCL) was the main pathological type, and the digestive system was the most extranodal involvement site in m-PTLD after KT and HSCT. Among the 28 patients with DLBCL m-PTLD,the complete remission rate after rituximab treatment was higher than in patients not administered rituximab treatment (P = 0.038). With a median follow-up of 46 months after m-PTLD diagnosis, the estimated 5-year overall survival (OS) was 59.2 ± 9.1% in all patients, and 64.2 ± 11.8 and 52.7 ± 14.1...Continue Reading

References

Nov 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T A ListerM Tubiana
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
Feb 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·V LeblondV Levy
Feb 21, 2004·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Gerhard Opelz, Bernd Döhler
Jun 28, 2005·Critical Reviews in Oncology/hematology·Anna L TaylorJ Andrew Bradley
Sep 28, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Irene M GhobrialChristopher G McGregor
Nov 24, 2006·The American Journal of Surgical Pathology·Lawrence R JohnsonSteven H Swerdlow
Dec 19, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Danielle CanioniLuc Xerri
Apr 22, 2008·British Journal of Haematology·Matthew J HouriganMaher K Gandhi
Jul 2, 2008·International Urology and Nephrology·Vahid PourfarzianiBehzad Einollahi
Sep 3, 2009·Blood·Helen E Heslop
Jan 21, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew M EvensSonali M Smith
Feb 21, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sophie CaillardBruno Moulin
Dec 6, 2014·Journal of Hematopathology·Christiane Stuhlmann-LaeiszWolfram Klapper

❮ Previous
Next ❯

Citations

Jan 27, 2019·Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society·Lukas Marcelis, Thomas Tousseyn

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.